company background image
BVXP

Bioventix AIM:BVXP Stock Report

Last Price

UK£33.50

Market Cap

UK£174.5m

7D

0%

1Y

-15.2%

Updated

04 Oct, 2022

Data

Company Financials +
BVXP fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends4/6

BVXP Stock Overview

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide.

Bioventix PLC Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bioventix
Historical stock prices
Current Share PriceUK£33.50
52 Week HighUK£40.00
52 Week LowUK£28.80
Beta0.37
1 Month Change3.88%
3 Month Change-1.47%
1 Year Change-15.19%
3 Year Change-5.37%
5 Year Change15.52%
Change since IPO1,617.95%

Recent News & Updates

Mar 31
Bioventix (LON:BVXP) Is Increasing Its Dividend To UK£0.52

Bioventix (LON:BVXP) Is Increasing Its Dividend To UK£0.52

Bioventix PLC ( LON:BVXP ) will increase its dividend on the 22nd of April to UK£0.52, which is 21% higher than last...

Shareholder Returns

BVXPGB BiotechsGB Market
7D0%1.1%-1.4%
1Y-15.2%-37.9%-14.4%

Return vs Industry: BVXP exceeded the UK Biotechs industry which returned -37.9% over the past year.

Return vs Market: BVXP matched the UK Market which returned -14.4% over the past year.

Price Volatility

Is BVXP's price volatile compared to industry and market?
BVXP volatility
BVXP Average Weekly Movement3.2%
Biotechs Industry Average Movement7.8%
Market Average Movement5.5%
10% most volatile stocks in GB Market10.8%
10% least volatile stocks in GB Market2.9%

Stable Share Price: BVXP is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: BVXP's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200312Peter Harrisonhttps://www.bioventix.com

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services.

Bioventix PLC Fundamentals Summary

How do Bioventix's earnings and revenue compare to its market cap?
BVXP fundamental statistics
Market CapUK£174.51m
Earnings (TTM)UK£6.62m
Revenue (TTM)UK£10.50m

26.4x

P/E Ratio

16.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BVXP income statement (TTM)
RevenueUK£10.50m
Cost of RevenueUK£752.96k
Gross ProfitUK£9.74m
Other ExpensesUK£3.12m
EarningsUK£6.62m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Oct 24, 2022

Earnings per share (EPS)1.27
Gross Margin92.83%
Net Profit Margin63.08%
Debt/Equity Ratio0.0%

How did BVXP perform over the long term?

See historical performance and comparison

Dividends

4.3%

Current Dividend Yield

90%

Payout Ratio